Safarzadeh M., et al., 2016 |
Iran |
Group A: Male- 19 Female- 22 Group B: Male- 21 Female- 26 |
Dry eye patients 41 in Group A 47 in Group B |
Tear Naturale (Alcon): dextran 70 -1 mg/ml, hypromellose 3 mg/ml, hydroxipropyl, metylcellulose, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, zinc chloride, sodiumhydrogen carbonate, carbono dioxide, purified water (non-preservative) |
Tearlose (Darou Company) Hydroxipropyl, methylcellulose 0.3 g, 0.1 g of dextran hydroxipropyl and 0.01% benzalkonium chloride as preservative |
a) OSDI scale of symptoms b) Rate of tear secretion-Schirmer test c) Rate of tear evaporation - TFBUT d) Staining in córnea e) conjunctival staining |
Group A: OSDI: 43.58 baseline, 31.92 after 4 weeks, (P<0.001) TFBUT baseline: 7 seg, and after 4 weeks: 7.62 (P=0.027) Conjunctival score: baseline: 6.67 and after 4 weeks: 5.53 (P<0.001) Corneal staining baseline:1.23 and after 4 weeks-0.44 (P<0.001) Schirmer: baseline 6.04 and after 4 weeks-6.56 (P=0.129) |
Group B: OSDI: 39.51 baseline, 29.97 after 4 weeks, (P<0.001) TFBUT baseline: 7.15 seg, and after 4 weeks: 8.09 (P=0.013) Conjunctival score: baseline: 7.34 and after 4 weeks: 5.09 (P<0.001) Corneal score baseline:1.15 Schirmer: baseline 6.64 and after 4 weeks-7.10 (P=0.115) |
Baseline: OSDI: P=0.339 TFBUT: P=0.640 Conjunctival staining: P=0.334 Corneal staining: P=0.807 Schirmer: P=0.676 after 4 weeks: OSDI: P=0.440 TFBUT: P=0.497 Conjunctival staining: P=0.822 Corneal staining: P=0.793 Schirmer: P=0.441 |
|
Perez-Balbuena AL, et al., 2016 |
Mexico |
Information about the multicenters are not compiled |
Mild to moderate dry eye patients 76 in Group XG/CS 72 in Group PEG/PG |
Xiel Ofteno -Sophia laboratories (0,09% xanthan gum/0,1% chondroitin sulfate preservative-free) |
Systane-Alcon (polyethylene glycol/propylene glycol) |
a) OSDI scale of symptoms b) Rate of tear secretion tax- Schirmer test c) Rate of tear evaporation - TFBUT d) corneal staining e) conjunctival staining |
Group A OR XG/CS: OSDI 19.3 baseline, 7.3 after 8 weeks (P=0.001) Schirmer: 6.4baseline, 11.0 after 8 weeks, (P=0.002) TBUT: baseline-5.5, 7.4 after 8 weeks (P=0.027) |
Group B OR PEG/PG OSDI: 19,3 baseline, 7.9 after 8 weeks (P=0.001) Schirmer: 6.5baseline, 10.5 after 8 weeks, (P=0.019) TBUT: 5.2baseline, 7.4, after 8 weeks (P=0.046) |
Says that is not statistically significant but do not say p's value |
- Do not say the P between the two groups - Refers to "staining" as a variable but do not says these results - Informatiosn about gender are not compiled |
Nelson, JD, et al., 1988 |
U.S.A |
Sodium hyaluronate (HS) Group: Male- 3 Female- 17 Polyvinyl alcohhol (PVA): Male- 1 Female- 14 |
Severe dry eye 20 in HS Group 15 in PVA Group |
Pharmacia - Piscataway, NJ (unpreserved 0,1% sodium hyaluronic purified water) |
Liquifilm - Allergan (1,4% polyvinyl alcohool with chlorabutanol 0,5%) |
a) Tear osmolarity b) Pain/analog scale c) Patients comments (symptoms) d) Eye drops frequency of use e) Visual acuity f) Rate of tear evaporation -TFBUT g) Rose bengal staining h) Rate of tear secretion- schirmer test i) Ocular surface impression citology |
Group A OR HS Group: a) Pain scale 65.9 baseline, 37.0 after 8 weeks b) Tear osmolarity 339.5 baseline, 312.0 after 8 weeks c) Schirmer 5.1 baseline, 6.5 after 8 weeks d) TFBUT 3.5 baseline, 4.9 after 8 weeks e) Rose bengal staining 4.0 baseline, 2.8 after 8 weeks f) Bulbar and palpebral impression citology Bulbar: 2.4 baseline, 2.3 after 8 weeks Palpebral: 1.3 baseline, 0.8 after 8 weeks |
Group B OR PVA Group a) Pain scale 67.6 baseline, 31.3 after 8 weeks b) tear osmolarity 371.4 baseline, 311.6 after 8 weeks c) Schirmer 5.3 baseline, 6.6 after 8 weeks d)TFBUT 4.8 baseline, 6.3 after weeks e) Rose bengal staining 3.1 baseline, 2.3 after 8 weeks f) Bulbar and palpebral impression citology Bulbar: 2.7 baseline, 2.3 after 8 weeks Palpebral: 1.0 baseline, 0.7 after 8 weeks |
Says that is not statistically significant but do not say p's value |
- Do not say the P between the two groups - Not detailed description of the variabels (visual acuity, frequency of use, symptoms comments) |
Astakhov, YS et al., 2013 |
Russia |
Hylabak Group: Male- 11 Female- 16 Systane Group: Male- 11 Female- 16 |
Mild dry eye after LASIK surgery 27 in HYLABAK Group 25 in SYSTANE Group |
Intervention: Hylabak, Abak, THEA Laboratories, (0,15% hyaluronato preservative -free) |
CONTROL Systane, Alcon (polyethylene glycol 0,4%, propylene glycol 0,3%, polidronium chloride 0,001% as preservative) |
a) Drymess b) Fluorescein satining c) Global tolerance d) Global efficacy and tolerance- investigator e) Best corrected visual acuity f) Rate of tear evaporation- TFBUT g) Lid-paralel conjunctival folds- lipcof test h) Slit lamp acessment- as blepharitis and meibomitis |
HYLABAK Group a) Dryness - no patients after 84 days b) Fluorescein staining-0.26 baseline, 0.11 after 12 weeks (P=0.16) c) Global efficacy and tolerance- investigator-one case "not satisfactory," 62.96% "very satisfactory" d) Best corrected visual acuity 59.26% had 6/6 in baseline, 81.48% had 6/6 after 12 weeks e) TFBUT-just describes p<0.0001, between baseline and after 12 weeks f) Lid-paralel conjunctival folds- lipcof test baseline: 55.56% no paralell fold 40.74% one parallel fold 1 severe parallel fold after 12 weeks: 81.48% no parallel fold, none severe parallel fold g) Slit lamp acessment - as blepharitis, meibomitis and flap edema baseline: flap edema -2 (7,41%) No one in day 84. after 12 weeks: One (3,7%) had flap folds |
SYSTANE Group a) Dryness - after 12 weeks: no patients b) Fluorescein staining- 0.11 baseline, 0.16 after 12 weeks (P=0.03) c) Global efficacy and tolerance- investigator- 37.04% "very satisfactory" d) Best corrected visual acuity 64% had 6/6 in baseline, 84% had 6/6 after 12 weeks e) TFBUT-just describes p<0.0001, between baseline and after 12 weeks f) Lid-paralel conjunctival folds- lipcof test baseline: 64% no paralell fold 24% one parallel fold 1 severe parallel fold after 12 weeks: 88% no parallel fold None severe parallel fold g) Slit lamp acessment- as blepharitis, meibomitis, and flap edema- baseline: 1 (4%) after 12 weeks: No one |
Says that is not statistically significant but do not say p's value Just statistically significant in 28 day in "global efficacy" to hylabak (P=0.0113) |
- Do not say the P between the two groups - No detailed description of the variabels (TBUT, symptoms, global tolerance scale. - Use of collors design graphics scales without exact numbers |